Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PCAF CRISPR Activation Plasmid (h): sc-400753-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PCAF CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- PCAF CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by PCAF CRISPR Activation Plasmid (h) and PCAF CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the KAT2B transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PCAF Antibody (E-8): sc-13124
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PCAF CRISPR Activation Plasmid (h) | sc-400753-ACT | 20 µg | $397.00 |
KAT2B encodes PCAF, a GNAT-family histone acetyltransferase that acetylates histones and non-histone substrates to modulate chromatin accessibility and transcriptional output. PCAF functions in multiprotein coactivator complexes and interfaces with transcription factors to regulate processes including cell cycle progression, DNA damage responses, and differentiation programs. Through acetylation-dependent control of gene expression, KAT2B/PCAF contributes to pathways linked to inflammatory signaling and oncogenic transcriptional networks. Dysregulated PCAF activity or expression has been associated with altered epigenetic states observed across multiple cancer contexts and other diseases involving transcriptional imbalance.
PCAF CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous KAT2B expression without altering the underlying DNA sequence.
PCAF CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the KAT2B locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the KAT2B transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous PCAF expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native KAT2B locus and enabling the study of PCAF-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of PCAF pathway restoration in tumor cells with silenced or reduced KAT2B expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.